The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Desar
Ingrid M E
IM
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. i.desar@aig.umcn.nl
Mulder
Sasja F
SF
Stillebroer
Alexander B
AB
van Spronsen
Dick-Johan
DJ
van der Graaf
Winette T A
WT
Mulders
Peter F A
PF
van Herpen
Carla M L
CM
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D011725:Pyridines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib